SCHEMBL6520362

SCHEMBL6520362

O=Cc1ccccc1C=Cc1ccc(Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 4/20 0.61
TDP1 Q9NUW8 2/20 0.52
MEN1 O00255 2/20 0.52
LMNA P02545 2/20 0.52
KMT2A Q03164 2/20 0.52
THRB P10828 1/20 0.52
BLM P54132 1/20 0.52
HSD17B10 Q99714 1/20 0.52
MAOB P27338 3/20 0.47
MAOA P21397 2/20 0.47
AHR P35869 1/20 0.47
CYP1A2 P05177 2/20 0.44
CYP1B1 Q16678 2/20 0.43
CYP1A1 P04798 1/20 0.43
RELA Q04206 1/20 0.43
FBP1 P09467 1/20 0.41
PPARG P37231 1/20 0.41
CHAT P28329 1/20 0.41
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15899333 1.00 NFE2L2 (0.61) NFE2L2TDP1MEN1LMNAKMT2A
SCHEMBL10458930 0.89 NFE2L2 (0.73) NFE2L2MEN1LMNAKMT2AHSD17B10
SCHEMBL10458456 0.89 NFE2L2 (0.73) NFE2L2MEN1LMNAKMT2AHSD17B10
SCHEMBL6480300 0.83 MEN1 (0.56) NFE2L2TDP1MEN1LMNAKMT2A
SCHEMBL6480298 0.83 MEN1 (0.56) NFE2L2TDP1MEN1LMNAKMT2A
SCHEMBL24385991 0.83 LMNA (0.62) NFE2L2TDP1MEN1LMNAKMT2A
SCHEMBL192399 0.83 LMNA (0.62) NFE2L2TDP1MEN1LMNAKMT2A
SCHEMBL192400 0.83 LMNA (0.62) NFE2L2TDP1MEN1LMNAKMT2A
SCHEMBL30958792 0.83 LMNA (0.62) NFE2L2TDP1MEN1LMNAKMT2A
SCHEMBL6525705 0.79 CYP1A2 (0.51) NFE2L2TDP1MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2759530-B1 Triphenylamine derivative, and charge transport material and electrophotographic photoreceptor using the same TAKASAGO PERFUMERY CO LTD (JP) 2015-09-23 EP disclosed
US-9128393-B2 Triphenylamine derivative, and charge transport material and electrophotographic photoreceptor using the same TAKASAGO INTERNATIONAL CORPORATION (JP) 2015-09-08 US disclosed
US-20140213822-A1 TRIPHENYLAMINE DERIVATIVE, AND CHARGE TRANSPORT MATERIAL AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR USING THE SAME TAKASAGO INTERNATIONAL CORPORATION (JP) 2014-07-31 US disclosed
EP-2759530-A1 Triphenylamine derivative, and charge transport material and electrophotographic photoreceptor using the same Takasago International Corporation (JP) 2014-07-30 EP disclosed
US-8680150-B2 Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors LIGAND PHARMACEUTICALS, INC. (US) 2014-03-25 US disclosed
US-20110003851-A1 SMALL MOLECULE HEMATOPOIETIC GROWTH FACTOR MIMETIC COMPOUNDS THAT ACTIVATE HEMATOPOIETIC GROWTH FACTOR RECEPTORS LIGAND PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003851-A1 SMALL MOLECULE HEMATOPOIETIC GROWTH FACTOR MIMETIC COMPOUNDS THAT ACTIVATE HEMATOPOIETIC GROWTH FACTOR RECEPTORS MPL, CSF3R, CSF1R NFE2L2 1683/4885TDP1 4283/4885MEN1 1652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.